Processes and intermediates for preparing BTK inhibitors
Patent Information
- Application Number
- JP2021569238
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-05-21
- Filing Date
- 2020-05-20
- Publication Date
- 2024-12-09
- Estimated Expiration
- 2040-05-20
AI Technical Summary
Existing methods for synthesizing Bruton's Tyrosine Kinase (Btk) inhibitors like ibrutinib lack efficient processes for forming N--N bonds in the core pyrazolopyrimidine heterobicycles, and there is a need for improved methods to produce enantioenriched compounds with high stereochemistry control.
A process involving copper-based catalysts and oxidizing agents is used to form N--N bonds in pyrazolopyrimidine heterobicycles, with specific conditions for nucleophilic substitutions and enantioselective reactions to produce compounds of formula (I), which can be further processed to yield ibrutinib with high enantiomeric excess.
The process allows for the production of ibrutinib with higher yields, purity, and selectivity, using fewer reagents and steps, and maintaining stereochemistry throughout, facilitating the production of enantioenriched pharmaceutical products.
Smart Images

Figure 2020234381000001 
Figure 2020234381000002 
Figure 2020234381000003
Abstract
Description
[Technical Field]
[0001] The present invention relates to a synthetic procedure and synthetic intermediates for substituted bicyclic compounds, particularly compounds useful as pharmaceuticals, such as Bruton's tyrosine kinase (Btk) inhibitors like ibrutinib. [Background technology]
[0002] Ibrutinib is an organic small molecule with the IUPAC name 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidine-1-yl]piperidine-1-yl]prop-2-en-1-one. It has been described in numerous published documents, including International Patent Application Publication International Publication No. 2008 / 039218 (Example 1b), as an irreversible inhibitor of Btk.
[0003] Btk plays a crucial role in the B cell signaling pathway, linking surface B cell receptor stimulation to downstream intracellular responses. Btk is a major regulator of B cell development, activation, signaling, and survival (Kurosaki, Curr Op Imm, 2000, 276-281; Schaeffer and Schwartzberg, Curr Op Imm 2000, 282-288). Furthermore, Btk plays a role in many other hematopoietic signaling pathways, such as macrophage TNF-α production mediated by Toll-like receptors (TLRs) and cytokine receptors, mast cell IgE receptor (FcepsilonRI) signaling, inhibition of the Fas / APO-1 apoptosis signaling ring in B-lineage lymphocytes, and collagen-stimulated platelet aggregation. For example, see: CAJeffries, et al., (2003), Journal of Biological Chemistry 278:26258-26264, NJHorwood, et al., (2003), The Journal of Experimental Medicine 197:1603-1611, Iwaki et al. (2005), Journal of Biological Chemistry 280(48):40261-40270, Vassilev et al. (1999), Journal of Biological Chemistry 274(3):1646-1656, and Quek et al (1998), Current Biology 8(20):1137-1140.
[0004] Ibrutinib is approved in several countries, including the United States and the EU, for certain hematological malignancies and is also being studied in clinical trials for other hematological malignancies. These malignancies include chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, and multiple myeloma.
[0005] In particular, there are many methods for preparing functionalized bicyclic heterocyclic compounds and ibrutinib, as described in U.S. Patent Application Publication No. 2011 / 0082137 and International Publication No. 2008 / 039218 (Example 1b). Regarding the latter, the ibrutinib synthesis step is shown in the following scheme: [ka]
[0006] It appears that the core heterobicyclic moiety of ibrutinib, namely pyrazolopyrimidine, is already constructed before the introduction of the chiral piperidinyl moiety. The bicyclic ring itself is constructed by preparing pyrazole intermediates substituted with amino and cyano groups at positions 3 and 4, respectively, and then reacting them with formamide.
[0007] Other methods for synthesizing ibrutinib are disclosed in the brochure for International Patent Application Publication No. 2014 / 139970, which includes the following scheme: [ka]
[0008] In this case, the core heterobicyclic ring of ibrutinib, namely pyrazolopyrimine, is constructed via an intermediate having a pyrazole ring substituted with amino and cyano groups at positions 3 and 4, respectively. From this intermediate, the pyrimidine moiety of the core heterobicyclic pyrazolpyrimidine can also be constructed, and subsequently further functionalized to form ibrutinib.
[0009] The final step for introducing the substituent on the nitrogen atom of the piperidinyl ring may be carried out according to the scheme described above, or by reacting with 3-chloropropionyl chloride (for example, in the presence of aqueous NaHCO3 in Me-THF) according to the procedure described in International Patent Application Publication International 2016 / 115356, thereby introducing a -C(O)-CH2CH2-Cl group to the nitrogen atom of piperidinyl. These intermediates are then subjected to an elimination reaction in the presence of DBU (1,8-diazabicyclo(5.4.0)undeca-7-ene) to yield ibrutinib.
[0010] The publications mentioned above do not disclose alternative methods for synthesizing the crucial pyrazolopyrimidine heterocyclic nucleus. Furthermore, synthesizing the NN bond (i.e., the combination of two nitrogen atoms) in relation to the ring is difficult. In this regard, the formation of indazoles is described in the academic paper "A synthesis of 1H-indazoles via a Cu(OAc)2-catalysed NN bond formation" by Chen et al., Organic Letters, 2016, 18, 1690-1693. However, this paper does not disclose the synthesis of the pyrazolopyrimidine heterocyclic nucleus at all. [Overview of the project]
[0011] A process for preparing the compound of formula (I) is provided. [ka] During the ceremony, R 1 This represents a nitrogen protecting group, R 2 represents hydrogen or aryl (e.g., phenyl), X 1 These are detaching groups (e.g., halo, -OY) 1 etc.) and -N(R 3 )R 4 Represents a substituent selected from, Y 1 is hydrogen or sulfone (e.g., -S(O)2-R x , wherein R x is C optionally substituted by one or more fluoro atoms 1~3 alkyl, or aryl (e.g., phenyl) optionally substituted by one or more substituents selected from halo and C 1~3 alkyl, the latter group being itself optionally substituted by one or more fluoro atoms), and thus, when X 1 represents -O-Y 1 a sulfonate group can be formed, for example X 1 can represent tosylate, mesylate, or triflate, R 3 and R 4 at least one of which represents a nitrogen protecting group and the other represents hydrogen or an independent nitrogen protecting group, This process involves the reaction of a compound of formula (II),
Chemical formula
[0012] This specification shows that salts of the compounds may be used and / or produced in the processes of the present invention (and embodiments described herein). Alternatively (and in preferred embodiments), free bases of the compounds may be used and / or produced. Furthermore, if the salt form is used and / or produced, it may be liberated to form a free base form (for example, for use in further process steps, such as those described herein, for further reactions). It should also be noted that the compounds described herein may exhibit isomerism, such as tautomerism.
[0013] To avoid any ambiguity, the compounds (and precursors) and downstream products of formula (I) have the (R) configuration in which the chiral center indicated by * in the exemplary examples below is: [ka] Here, it is shown that compounds (e.g., formulas (I), (II), (III), etc.) exist, in which an atom in the (R) configuration is present, meaning that the (R)-enantiomer is the main enantiomer and the compound has an enantioenrichment of more than 20% (and, in embodiments, a higher enantioenrichment). For example, enantioenriched compounds (e.g., compounds of formulas (I), (II), (III), etc.) may have an enantiomeric excess of more than 40%, e.g., more than 60%, and in one embodiment, an enantiomeric excess of more than 80%. Enantioenriched compounds may even have an enantiomeric excess of more than 90% (e.g., they may consist substantially of a single enantiomer, meaning that the enantioenrichment of more than 95%, e.g., more than 98% or about 100%). Such enantioenrichments (or enantioenrichments) can be obtained directly or by further purification techniques known to those skilled in the art.
[0014] For example, the processes of some embodiments of the present invention produce enantioen-rich products. As an example, the compound of formula (V) used in the processes of the present invention described herein (in the reaction with the compound of formula (IV) to produce the compound of formula (III)) is enantioen-rich, i.e., consisting of the ee described herein (e.g., more than 80% ee). When enantiospecificity is introduced into the process, downstream reaction / process steps can become stereospecific. That is, the stereochemistry is maintained in the downstream product, i.e., the ee of the compound of formula (III) is associated with the ee of the precursor compound of formula (V) obtained. Similarly, the ee of the compound of formula (I) is associated with the ee of the compound of formula (III) obtained (and so on). Downstream process steps can also become stereospecific and maintain such stereochemistry that is favorable for producing the final pharmaceutical product which is a single enantiomer such as ibrutinib. The fact that enantioselectivity is introduced early in the reaction scheme is advantageous in terms of efficiency because there is less product wasted. [Modes for carrying out the invention]
[0015] In the process of the present invention described herein, a new NN bond is formed during the preparation of the compound of formula (I). To achieve this, in one embodiment, a suitable copper-based catalyst is used. Such reactions are carried out in the presence of an oxidizing agent such as O2 in the air. Suitable catalysts that may be used include Cu(OAc)2, CuBr, and other copper halides in which the halide may be fluoro, iodine, bromo, and chloro, particularly chloro and bromo (especially chloro). 1 Compounds of formula (II) where X represents a halo (e.g., chloro) are formed in the presence of a specific copper catalyst (e.g., Cu(OAc)2) where X 1 It is converted to a compound of formula (I) representing -OH, but in the presence of other copper catalysts (e.g., copper halides), X 1 The identity of the part may be preserved.
[0016] The compound of formula (II) is the compound of formula (III). [ka] or its salt (wherein R 1 and X 1 (As defined above) and the compound of formula (IV) [ka] or its salt (wherein R 2 As defined by, X 2 It can be prepared by reaction with an organometallic base, particularly an organolithic base (which represents a halo group), in which case lithium is interchangeable with the halo group (X 2 In this reaction, a nucleophile is formed, which bonds with the carbon atom of the cyano moiety of the compound of formula (III), ultimately forming the imine moiety of the desired compound of formula (II). This reaction, and the crucial part of forming organolithium, can be carried out in the presence of a suitable polar aprotic solvent, such as THF.
[0017] The compound of formula (III) is the compound of formula (V). [ka] or its salt (where X 1 X is defined as above, 3 is a halo (e.g., chloro, bromo, or iodine) or -OY 2 Suitable withdrawal groups include Y 2 This is a sulfone (e.g., -S(O)2-R y (R in the formula y C is a carbon atom that is optionally substituted with one or more fluoro atoms. 1~3 Alkyl, or optionally halo and C 1~3 It can represent an aryl (e.g., phenyl) substituted with one or more substituents selected from alkyl, the latter group itself may be optionally substituted with one or more fluoro atoms)) and thus X can be prepared by the reaction of X 3 This is the compound of formula (VI). [ka] or its salt (R in the formula) 1 X (as defined above) can form sulfonates (e.g., tosylates, mesylates, or triflates) under nucleophilic aromatic substitution conditions, and for such a reaction to proceed successfully, 3 The group acts as a good leaving group, and the ortho-cyano substituent acts as a suitable electron-withdrawing moiety to promote nucleophilic substitution. This reaction can be carried out in the presence of a suitable base, such as a carbonate base, for example, an alkali metal carbonate, Na2CO3, or the like.
[0018] The compound of formula (VI) can be prepared by division. In further embodiments of the present invention, the following processes / methods may be used.
[0019] Certain starting materials and intermediates may also be commercially available or can be prepared according to conventional reaction procedures generally known in the art.
[0020] Every individual feature referred to herein (e.g., preferred feature) may be interpreted alone or in combination with any other feature referred to herein (including preferred features) (and thus preferred features may be interpreted together with or independently of other preferred features).
[0021] Those skilled in the art will understand that the compounds referred to in the context of the process of the present invention are stable. That is, the compounds included herein are robust enough to withstand, for example, isolation from a reaction mixture to a useful degree of purity.
[0022] In one embodiment of the present invention, compounds of the following formula (I) are provided by the process of the present invention, which are X 1 is a halo (for example, chloro) or -OY 1Represents and / or Y 1 This represents hydrogen.
[0023] In further embodiments of the present invention, compounds of the following formula (I) are provided by the process of the present invention, which are: R 2 This represents phenyl (which is unsubstituted and forms the appropriate substituents contained in ibrutinib).
[0024] In this specification, the compound of formula (I) prepared by the process described herein is defined as having R in formula (I). 1 It is stated that this represents a nitrogen protecting group. In this regard, the following protecting groups, namely, - Amides (e.g., N-acetyl) -Optionally substituted N-alkyl (e.g., N-allyl, or optionally substituted N-benzyl) -N-sulfonyl (e.g., N-benzenesulfonyl which is optionally substituted) - Carbamate -urea It should be understood that this includes substances that lead to the formation of trityl(triphenylmethyl) and diphenylmethyl.
[0025] Therefore, R 1 This can represent the following: -C(O)R t1 (In the formula, R t1 is C 1~6 (may represent an alkyl group, or an optionally substituted aryl group), C 1~6 Alkyl (the alkyl group is optionally substituted by one or more substituents selected from optionally substituted aryl groups) (for example, it may form a benzyl moiety), -S(O)2R t2 (In the formula, R t2 (where can represent an aryl that is optionally substituted), or in one embodiment, -C(O)OR t3 (In the formula, R t3is an aryl that is optionally substituted, or, in a further embodiment, an aryl that is optionally substituted. 1~6 (For example C 1~4 ) may represent an alkyl group, for example, tert-butyl (therefore, for example, it forms a tert-butoxycarbonyl protecting group, which in turn forms a tert-butylcarbamate group when combined with the amino moiety), or a -CH2 phenyl group (therefore, it forms a carboxybenzyl protecting group), -C(O)N(R t4 )R t5 (In one embodiment, R t4 and R t5 These are, independently, hydrogen and C 1~6 Alkyl, optionally substituted aryl, or -C(O)R t6 Represents R t6 is C 1~6 (Represents an alkyl group or an aryl group substituted with any optional compound.)
[0026] In one embodiment, R 1 is -C(O)OR t3 (In the formula, R t3 is C 1~6 It represents an alkyl group, for example, tert-butyl, and therefore, in one embodiment, R 1 The protecting group is tert-butoxycarbonyl (also known as BOC or Boc group, and referred to as BOC or Boc group herein).
[0027] However, R 1 The selection of protecting groups that can be represented in the processes described herein is flexible. Furthermore, in any of the compounds described herein, if it is advantageous, for example, for a particular protecting group to be used in a particular process step (and for a different protecting group to be used in a subsequent or preceding process step), then a certain R 1 Protecting group to another R 1 It can be converted into a protecting group.
[0028] (For example, X in the formula) 1 is a halo (e.g., chloro) or -OY 1To provide a compound of formula (I) represented by), the compounds of formula (II) that can be used in the process of the present invention include, where X 1 Those in which represents halo (e.g., chloro) are exemplified. In particular, where X 1 represents halo (e.g., chloro) in the compound of formula (II) are (according to the procedures described herein) compounds of formula (I) in which X 1 represents halo (e.g., chloro) or -OH (i.e., where Y 1 represents hydrogen, -OY 1 ).
[0029] In a further embodiment, depending on the desired downstream product to be synthesized, a particular compound of formula (I) can be converted into other compounds of formula (I). For example, in the process described herein, when a compound of formula (I) in which X 1 represents -OH is provided, such X 1 groups may be converted to a better leaving group, e.g., where X 1 represents -OY 1 , and Y 1 represents a group where the sulfone (i.e., -S(O)2-R x ), and where R x is as defined above, there may be a case where it is desirable to convert. Such conversions can be useful, for example, in providing further downstream products (e.g., via nucleophilic aromatic substitution reactions) in order to introduce other substituents (a more varied array) at the X 1 position. Such a compound of formula (I) (where X 1 represents -OY 1 , and where Y 1 represents -S(O)2-R x ) is obtained by reacting a corresponding compound in which X 1 represents -OH with a compound of formula LG-S(O)2-R x (where R x is as defined above, and LG represents a suitable leaving group such as halo, but may also represent an -OS(O)2-R x group, where R x is as defined herein, and the two R xThe bases may be the same or different, but are preferably the same), and can be prepared therefrom. Such reactions can occur in the presence of a base and optionally a suitable solvent (for example, they can occur in the presence of pyridine). As an example, in the formula X 1 A compound of formula (I) in which represents -OH can react, for example, in the presence of pyridine, with trifluoromethanesulfonic anhydride, i.e., (CF3SO2)2O or F3C-S(O)2-O-S(O)2CF3, and thus a triflate leaving group can be formed. In a similar manner, other leaving groups such as mesylate and tosylate can also be formed.
[0030] In the formula R 2 A compound of formula (I) in which represents aryl (for example phenyl) can, for example, have the following formula R 2a -L xa (where R 2a represents aryl, for example phenyl, and L xa represents a suitable leaving group or linking group such as -B(OH)2, -B(OR w )2, or -Sn(R w )3, and in the formula each R w independently represents a C 1~6 alkyl group, or, in the case of -B(OR w )2, the respective R w groups can be bonded together to form a 4- or 6-membered cyclic group (for example, a 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl group, thereby forming, for example, a pinacolato boronate group), and here such groups can be prepared from the corresponding compounds having a halo atom), by reacting a compound of formula (I) in which R 2These can be prepared from compounds of the corresponding formula (I) where represents hydrogen, and these reactions can be carried out in the presence of an optionally suitable base (e.g., carbonate bases, hydroxide bases, etc.) and a suitable solvent, a suitable catalyst system (palladium is a preferred catalyst) such as metals (or their salts or complexes) such as Pd, CuI, Pd / C, Pd(OAc)2, Pd(Ph3P)2Cl2, Pd(Ph3P)4, Pd2(dba)3 and / or NiCl2, and a ligand such as PdCl2(dppf).DCM, t-Bu3P.
[0031] Compounds of formula (I) (for example, X in formula) 1 However, halo (e.g., chloroform), or Y in the formula 1 -S(O)2-R x -OY represents 1 (These represent "detaching groups"), followed by X in the formula. 1 ga-N(R 3 )R 4 (R in the formula 3 and R 4 X can be converted into other compounds of formula (I) that represent the compound of formula (I) as defined above. Such a compound can be converted into, for example, a compound of formula (I) (where X is as defined above). 1 (where represents the appropriate "leaving group"), use the following formula HN(R 3 )R 4 The compound (where R is in the formula) 3 and R 4 The protecting groups can be converted by reacting them with the protecting groups defined above (and preferably both representing hydrogen, or at least one representing hydrogen and the other representing hydrogen or the nitrogen protecting group defined above). Protecting groups that may be mentioned include those defined above, and in one embodiment, benzyl or PMB (4-methoxybenzyl). If desired, such protecting groups can be removed by methods described herein or known to those skilled in the art.
[0032] In one embodiment, a compound (for example, X in formula X) is prepared according to the procedure described. 1 represents -NH2, R 2R represents an unsubstituted phenyl molecule, 1 A compound of formula (I), in which represents a hydrogen or nitrogen protecting group, in which case the nitrogen protecting group can be removed according to the description herein, can then be used to prepare ibruintib. For example, under the conditions described in either International Publication No. 2014 / 139970 or International Publication No. 2016 / 115356, such a compound may be reacted with Cl-C(O)-C(H)=CH2, or a two-step process may be carried out by reacting it with 3-chloropropionyl chloride (for example, in the presence of aqueous NaHCO3 in Me-THF) to thereby prepare a compound of formula (VII). [ka] Alternatively, derivatives thereof may be formed, and such intermediates can be subjected to elimination reactions, for example, in the presence of DBU(1,8-diazabicyclo(5.4.0)undeca-7-ene) to yield ibrutinib.
[0033] To avoid any doubt, the formula for ibrutinib (as prepared in the embodiments of this invention) is as follows: [ka]
[0034] Unless otherwise specified, alkyl groups as defined herein may be linear, branched, and / or cyclic if they contain a sufficient number of carbon atoms (i.e., at least three). Furthermore, if they contain a sufficient number of carbon atoms (i.e., at least four), such alkyl groups may also be partially cyclic / acyclic. Moreover, such alkyl groups may be saturated, or unsaturated if they contain a sufficient number of carbon atoms (i.e., at least two) (and thus include, for example, a "vinyl" moiety).
[0035] The process of the present invention produces an enantioen-rich form or product, meaning that the resulting product has an enantiomeric excess of more than 20%, for example more than 40%, for example more than 60%, and in one embodiment more than 80%. The enantioen-rich product may even exceed 90% (for example, they may consist substantially of a single enantiomer, meaning that the ee may be 95% or more, for example more than 98% or about 100%). Such enantioenrichments (or ees) can be obtained directly or by further purification techniques known to those skilled in the art.
[0036] To avoid any ambiguity, when referring to equivalents, this shall mean molar equivalents.
[0037] In a further aspect of the present invention, a process is provided for separating the obtained product (compound of formula (I)) from the process of the present invention (which may be referred to herein as "the compound of the present invention"). Thus, the compound of the present invention (or the product obtained by the process of the present invention) can be separated / isolated. This can be achieved in several ways: - Flash column chromatography - Precipitation / crystallization - Derivatization, followed by optional precipitation / crystallization. - Extraction (e.g., extraction after derivatization) -distillation.
[0038] In further embodiments of the present invention, a process of the present invention as described herein is provided, which is subsequently followed by further process steps.
[0039] The compound of formula (I) (enantioenriched form) can be used to prepare further compounds, such as pharmaceuticals (or intermediates thereof) useful for treating cancer (e.g., hematological malignancies), specifically, the pharmaceutical may be ibrutinib.
[0040] Other transformations (of the products obtained directly by the process of the present invention, or of further products obtained from downstream processes that may be described herein, for example) can be carried out according to standard methods and processes of the prior art, such as amide formation reactions (in which case the possible conditions and coupling reagents will be known to those skilled in the art), esterification, nucleophilic substitution reactions, and aromatic nucleophilic substitution reactions.
[0041] Next, a process for preparing a pharmaceutical formulation containing ibrutinib is provided, which includes associating ibrutinib (or a pharmaceutically acceptable salt thereof) prepared according to the process described above with a pharmaceutically acceptable excipient, adjuvant, diluent, and / or carrier.
[0042] Generally, the processes described herein may have the advantage that the compounds to be prepared can be produced in a manner that utilizes fewer reagents and / or solvents and / or requires fewer reaction steps (e.g., different / separate reaction steps) compared to processes disclosed in the prior art.
[0043] Furthermore, the process of the present invention may offer advantages such as the compound being prepared having a higher yield, higher purity, higher selectivity (e.g., higher regioselectivity), being produced in a shorter time, in a more convenient (i.e., easier-to-handle) form, from a more convenient (i.e., easier-to-handle) precursor, at a lower cost, and / or with less use and / or loss of materials (including reagents and solvents), compared to procedures disclosed in the prior art. In addition, several environmental advantages may exist for the process of the present invention. [Examples]
[0044] The following examples are intended to illustrate the present invention and should not be construed as limiting the scope of the invention.
[0045] Preparation of compounds 6 and 7: Compound number 5 is prepared (from compounds 1, 2, 3, and 4) according to the basic procedure of the scheme below. Then, compound 5 is converted to compounds 6 and 7 under the specific conditions described below: (i) Under conditions of dry air, using CuBr as a catalyst and DMA as a solvent, compound 6 is the main product, accompanied by 10-20% of compound 7 as a byproduct. The isolation yield of compound 6 is approximately 55.8%. (ii) Under conditions of air (not dry / not dried), using Cu(OAc)2 as a catalyst and DMSO as a solvent, compound 7 is the main product, accompanied only by trace amounts of compound 6. The isolation yield of compound 7 is 44.2%. [ka]
[0046] The pathway from compound 7 to compound 11: Although this reaction was successful, the yield was low due to the instability of compound 8. The -OH group was activated by reaction with Tf2O (to form the corresponding triflate, i.e., compound 8), and this was subsequently substituted in three different ways. [ka]
[0047] Compound 8 was reacted with amines in three different ways (using three different amines) as shown above: (i) NH2Bn (benzylamine); (ii) NH3 (ammonia); and (iii) NH2PMB (4-methoxybenzylamine). These are shown in the scheme below. The substitution reaction (i) with NH2Bn was successful, but in the deprotection step, i.e., the "de-Bn" step, the main product was excess hydrogenation, and the yield of compound 9 was found to be very low. The above substitution reactions (ii) and (iii) with NH3 and NH2PMB were successful, respectively, but did not proceed in very high yields. Therefore, the yields for compounds 10 and 12 from reactions (ii) and (iii) were low. [ka]
[0048] The pathway from compound 6 to compound 11: There are three routes to obtain compounds 6 through 10, according to the scheme below. The first route involves bubbling NH3 into a solution of compound 6 in DMA (dimethylacetamide) in the presence of CuBr. Compound 10 was obtained in 92.5% yield. The second route uses Cu2O as a catalyst, NMP (N-methyl-2-pyrrolidine) as a solvent, and NH4OH as a reagent. Compound 10 was obtained in 67.2% yield. The third route involves first reacting compound 12 with PMBNH2 (4-methoxybenzylamine) to form compound 12, and then using DDQ (2,3-dichloro-5,6-dicyano-1,4-benzoquinone) to deprotect the PMB (4-methoxybenzyl) group. Compound 10 was obtained in 57.3% yield (89.1% × 64.2%). The yield from compound 10 to compound 11 was 73.1%. [ka]
[0049] Final synthetic route for compound 11 (an important intermediate in ibrutinib synthesis) This pathway uses a single (R)-enantiomer of starting material 2 (see below), labeled "2R" (where downstream single enantiomers are produced, which are subscripted with "R" compared to the numbering used in the scheme above). [ka]
[0050] Compound 1 and Compounds 2R through 3R Experiment details Compound 1 (50.01 g, 289 mmol) and Compound 2R (75.24 g, 376 mmol, 1.3 eq.) were dissolved in dry THF (550 mL, 11 V) mixed with sodium carbonate (30.6 g, 289 mmol, 1.00 eq.). The mixture was stirred under N2 at 33 °C for 24 hours, then the reaction was quenched by adding water (500 ml, 10 V), followed by phase separation. The organic layers were washed again with water (250 ml, 5 V), and the aqueous layer was extracted twice with EA (ethyl acetate) (250 ml, 5 V). The organic layers were combined, and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography (PE:EA = 15:1 to 5:1) to obtain 55.56 g of compound 3R in an overall yield of 57.19% (35.03 g at 99.20% purity and 20.53 g at 98.59% purity).
[0051] Compound 3R and Compounds 4 through 5R Experiment details Compound 4 (65.03 g, 262 mmol, 3 eq.) was dissolved in dry THF (300 mL, 10V) and subsequently cooled to -70 to -75°C. Then, under N2 conditions at -70 to -75°C, a THF solution of n-BuLi (16.73 g, 261 mmol, 3 eq.) was added dropwise to the THF solution of Compound 4. Compound 3R (29.45 g, 87.4 mmol, 1 eq.) was dissolved in dry THF (300 mL, 10V) and subsequently added dropwise to the above intermediate solution under N2 conditions at -70 to -75°C. After stirring for 1 hour, saturated ammonium chloride (300 mL, 10V) was added dropwise to the reaction mixture to quench the reaction. The solvent was evaporated under reduced pressure, and the crude product was purified by column chromatography (PE:EA = 10:1 to 3:1) (petroleum ether / ethyl acetate) to obtain 30.95 g of compound 5R in an overall yield of 69.88% (2.63 g at 98.21% purity and 28.32 g at 91.51% purity).
[0052] Compounds 5R to 6R Experiment details Compound 5R (1.05 g, 2.1 mmol), CuBr (148.3 mg, 0.5 eq), and dried DMA (10 ml, 10V) were added to a dry flask, and the reaction mixture was subsequently heated to 85°C and stirred for 10 hours under a stream of dry air. EA (10 ml, 10V) was added to the mixture, and the organic layer was washed twice with water (100 ml, 10V). The solvent was evaporated under reduced pressure, and the crude product was purified by column chromatography (PE:EA = 10:1) to obtain 0.48 g of compound 6R (HPLC purity 98.61a%) in yield 45.89%.
[0053] Compounds 6R to 10R Experiment details Compound 6R (1.72 g, 3.4 mmol) was dissolved in DMA (12 ml, 7V) in an autoclave, followed by bubbling with NH3 for 25 minutes. CuBr (240 mg, 0.5 eq) was added to the reaction mixture, and the mixture was then heated to 85°C. After stirring for 16 hours, EA (26 ml, 15V) was added, and the organic layer was washed three times with water (17 ml, 10V). The solvent was evaporated under reduced pressure, and the crude product was purified by column chromatography (PE:EA = 5:1 to 2:1) to obtain 1.53 g of compound 10R (HPLC purity 99.15a%) in 92.5% yield.
[0054] Compounds 10R to 11R Experiment details Compound 10R (1.03 g, 2.1 mmol) was dissolved in toluene (8 ml, 8 V), followed by the sequential addition of water (7.5 ml, 7.5 V), and then 35% HCl (2.21 g, 21 mmol, 10 eq.). The reaction mixture was heated to 65°C and stirred for 2 hours. The mixture was cooled to 20-25°C, and the phases were separated. MeOH (5 ml, 5 V) was added to the mixture, and the pH was adjusted to 10-13 with 30% KOH. The solids were filtered, and the cake was washed with 50% by weight MeOH / H2O (1 g). The wet cake was dissolved in MeOH (17 ml, 17 V) at 45°C, followed by the dropwise addition of 50% by weight KOH / H2O (14 g, 14 X). The mixture was cooled to 20-25°C, followed by filtration of the solids, and the cake was washed with 50% by weight MeOH / H2O (1 g). After drying under reduced pressure at 45°C for 16 hours, 0.69 g of compound 11R was obtained (HPLC purity 99.7a%, 100% chiral). The yield was 86.9%.
[0055] Compound 11R is derived from ibrutinib Ibrutinib was prepared according to the procedures disclosed in International Publication No. 2016 / 115356, International Publication No. 2008 / 039218 (Example 1b), and / or International Publication No. 2014 / 139970.
[0056] Further Example A: Ibrutinib (or a salt thereof) is prepared by preparing an intermediate using one of the process steps described in Example 1, and then converting it to ibrutinib (or a salt thereof).
[0057] Further Example B: A pharmaceutical composition is prepared by first preparing ibrutinib (or a salt thereof) according to Example 2, and then contacting the ibrutinib (or a salt thereof) thus obtained with a pharmaceutically acceptable carrier, diluent, and / or excipient.
Claims
1. A process for preparing a compound of formula (I), comprising: [Formula 1] During the ceremony, R 1 represents a nitrogen protecting group, R 2 represents hydrogen or aryl; X 1 is a leaving group and -N(R 3 ) R 4 represents a substituent selected from R 3 and R 4 at least one of represents a nitrogen protecting group and the other represents hydrogen or an independent nitrogen protecting group; The process comprises reacting a compound of formula (II) in the presence of an oxidizing agent and a copper-based catalyst, [Case 2] In the formula, R 1 , R 2 , and X 1 is as defined above.
2. The process of claim 1, wherein the oxidant is an oxygen source.
3. The reaction is carried out in the presence of a copper-based catalyst and air (O 2 3. The process according to claim 1 or 2, carried out in the presence of
4. The catalyst used is Cu(OAc) 2 or CuBr.
5. R 2 represents hydrogen or phenyl; X 1 is selected from halo, -O-Y 1 and -N(R 3 )R 4 ; 5. The process according to any one of claims 1 to 4, wherein Y 1 represents hydrogen or -S(O) 2 -R x , wherein R x represents C 1-3 alkyl optionally substituted by one or more fluoro atoms, or represents phenyl optionally substituted by one or more substituents selected from halo and C 1-3 alkyl optionally substituted by one or more fluoro atoms.
6. X 1 is halo or -O-Y 1 and / or Y 1 represents hydrogen, and / or R 2 The process of any one of claims 1 to 5, wherein represents phenyl.
7. The process of claim 1, wherein X 1 is chloro or represents tosylate, mesylate, or triflate.
8. The compound of formula (II) is a compound of formula (III) [C3] or a salt thereof (wherein, R 1 and X 1 is as defined above) and a compound of formula (IV) [C4] or a salt thereof (wherein, R 2 is as defined, and X 2 The process according to any one of claims 1 to 7, wherein the compound is prepared by reaction with a halogen atom,
9. The compound of formula (III) is a compound of formula (V) [C5] or a salt thereof (wherein X 1 is as defined above, and X 3 is halo or -O-Y 2 represents a leaving group selected from 2 represents a sulfone), and Compound of formula (VI) [C6] or a salt thereof (wherein R 1 is as defined above) under nucleophilic aromatic substitution reaction conditions.
10. The process of claim 9, wherein X 3 is chloro, bromo or iodo, or represents -O-Y 2 , and Y 2 represents -S(O) 2 -R y , where R y represents C 1-3 alkyl optionally substituted by one or more fluoro atoms, or represents phenyl optionally substituted by one or more substituents selected from halo and C 1-3 alkyl optionally substituted by one or more fluoro atoms.
11. The process of claim 9 or 10, wherein X 3 represents tosylate, mesylate, or triflate.
12. A process for the preparation of Ibrutinib comprising the conversion of a compound of formula (I) [Formula 1] X in the formula 1 Ha-NH 2 represents R 2 represents unsubstituted phenyl; R 1 represents hydrogen or a nitrogen protecting group; The compound of formula (I) is prepared by the process according to any one of claims 1 to 11.
13. 13. The process of claim 12, wherein the compound of formula (I) is converted to ibrutinib.
14. The conversion of the compound of formula (I) comprises reacting said compound of formula (I) with Cl-C(O)-C(H)=CH 2 , or The compound of formula (I) is reacted with 3-chloropropionyl chloride to give a compound of formula (VII) [C7] and said compound of formula (VII) is subjected to an elimination reaction to give ibrutinib.
14. The process of claim 12 or 13, comprising:
15. The two-step process, wherein the reaction of the compound of formula (I) with 3-chloropropionyl chloride is carried out in the presence of aqueous NaHCO 3 in Me-THF; 15. The process of claim 14, wherein the elimination reaction is carried out in the presence of DBU (1,8-diazabicyclo(5.4.0)undec-7-ene).
16. A process for preparing a pharmaceutical composition comprising ibrutinib or a salt thereof, comprising preparing ibrutinib or a salt thereof as described in any one of claims 12 to 15 and then contacting it with a pharma- ceutically acceptable carrier, diluent, and / or excipient.
